Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Net Income (2016 - 2025)

Kiora Pharmaceuticals' Net Income history spans 11 years, with the latest figure at -$6.5 million for Q4 2025.

  • For Q4 2025, Net Income fell 53.87% year-over-year to -$6.5 million; the TTM value through Dec 2025 reached -$10.8 million, down 400.92%, while the annual FY2025 figure was -$10.8 million, 400.92% down from the prior year.
  • Net Income reached -$6.5 million in Q4 2025 per KPRX's latest filing, down from $26806.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $13.5 million in Q1 2024 to a low of -$14.4 million in Q4 2021.
  • Average Net Income over 5 years is -$2.6 million, with a median of -$2.5 million recorded in 2021.
  • Peak YoY movement for Net Income: tumbled 1126.36% in 2021, then surged 801.91% in 2024.
  • A 5-year view of Net Income shows it stood at -$14.4 million in 2021, then skyrocketed by 74.26% to -$3.7 million in 2022, then surged by 43.87% to -$2.1 million in 2023, then plummeted by 103.14% to -$4.2 million in 2024, then tumbled by 53.87% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Net Income are -$6.5 million (Q4 2025), $26806.0 (Q3 2025), and -$2.2 million (Q2 2025).